SCIENCEDOMAIN international

www.sciencedomain.org



SDI Review Form 1.6

Journal Name:	Asian Journal of Applied Chemistry Research
Manuscript Number:	Ms_AJACR_48651
Title of the Manuscript:	Validated Stability Indicating HPTLC, UHPLC and UV-Spectrophotometric Techniques for the Determination of Bepotastine Besilate
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that <u>NO</u> manuscript should be rejected only on the basis of '<u>lack of Novelty'</u>, provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (10-04-2018)

SCIENCEDOMAIN international www.sciencedomain.org



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write
On the DEVIOLON of the DEVIOLON of the DEVIOLENCE OF THE DEVIOLENCE OF THE DEVICE OF T		his/her feedback here)
Compulsory REVISION comments	A True also talle as a Prosition by H	
	1- Title should be modified to be "	
	Validated Stability Indicating HPTLC, UHPLC and UV-Spectrophotometric Techniques for	
	the Determination of Bepotastine Besilate in presence of its oxidative degradate . to be	
	distinctive your work	
	2- Introduction is too short , please add more details	
	Bepotastine besilate (Bepotastine-B) (its chemical structure is demonstrated in	
	scheme 1) add it please	
	Including RP-HPLC techniques [3-5]; among these methods is method of LC-	
	MS/MS one [reference 5] discuses it in details; and also and stability indicating	
	HPTLC determination of Bepotastine-B in presence of its acid degradate [6],	
	discuss it in details because you choose it as reference method	
	3- Experimental; add (twon, country) for each instrument and chemicals, like,	
	USA; RAMEDA CO, (, Egypt);, UK	
	4- Preparation of degradation product; why you did not try 30 % H2O2 to reduce	
	waiting time (2 days is too long time)?however, your method of preparation of	
	oxidative degradate is very wonderful where no standard was available	
	5- In 2.3.1 linearity, why you choose 266 nm in HPTLC and 260 nm in UPLC method	
	, I think it should be the same detection wavelength	
	6- In TLC method, it is very clear that normol TLC was not suitable for the drug	
	because of very clear tailing; why you did not try RP-TLC, however you can add it	
	to future research plane to improve peak shape and reduce tailing .	
	7- In results and discussion; check the mass spectrum of oxidative degradate, you	
	will found very clear peak at 163.18 m/z, give explanation please	
	8- 1.3 application to pharmaceutical formulations (remove s in all manuscript please	
	one tablet dosage form), while UV-spectrophotometric methods are more simple	
	, this is not true because it does not include direct measurement in zero order.	
	you can say that UV spectrophotometer is cheap and easily available instrument	
	you can say that o'v spectrophotometer is cheap and easily available instrument	
Minor REVISION comments		
MINO NE VIOION COMMONO	9- Add future research plane after discussion; like application of the methods for	
	determination of the drug in presence of acid degradates, alkaline degradates and	
	photo degradation products	
	prioto degradation products	
Optional/General comments	No comments	

PART 2:

		Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Mohamed Gamal Mahmoud
Department, University & Country	Jouf university , Saudi Arabia

Created by: EA Version: 1.6 (10-04-2018) Checked by: ME Approved by: CEO